THURSDAY, Dec. 3, 2020 — For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free survival, according to a study published in the Dec. 3 issue of the New…
Read More
Laparoscopic resection may be an option for CRC liver metastases
(HealthDay)—For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for treatment with laparoscopic versus open liver resection, according to a study published online Nov. 17 in the Annals of…
Read More
Disparities seen in outcomes for young adults with CRC
(HealthDay)—Worse outcomes are seen for young adult (YA) patients with colorectal cancer (CRC) living in the lowest income and education areas, according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan….
Read More